The t(10;11)(p13;q14-21) is a non-random translocation that occurs primarily in T cell acute lymphoblastic leukemias (T-ALL), but has also been observed in leukemias and lymphomas of diverse lineages. In U937, a cell line established from a diffuse histiocytic lymphoma, a t(10;11)(p13;q14-21) fuses AF10 to CALM. AF10 is also fused to MLL by a translocation that appears quite similar at the cytogenetic level, the t(10;11)(p12;q23). Fluorescence in situ hybridization studies have demonstrated that AF10 and CALM are also involved in other hematological malignancies containing t(10;11)(p13;q21), but no data are available concerning the molecular details of AF10-CALM fusion in primary leukemias. Using RT-PCR, we amplified multiple different isoforms of AF10-CALM and CALM-AF10 fusion cDNAs from a primary T cell ALL containing a t(10;11)(p13-14;q14-21). These cDNAs arose via alternative splicing of exons from both AF10 and CALM, which we demonstrated can also occur in the native genes. We identified at least two novel AF10 exons that can be included in wild-type and fusion cDNAs. The majority of the AF10 and AF10-CALM cDNA isoforms that we identified are predicted to encode for truncated AF10 polypeptides, raising the possibility that these might have important cellular functions in normal and malignant cells, perhaps by acting as dominant negative inhibitors of fulllength AF10 or related proteins.
Introduction
Translocations between the short arm of chromosome 10 and the long arm of chromosome 11 have been reported in acute myeloid leukemias (AML), acute lymphoblastic leukemias (ALL) and non-Hodgkin's lymphomas (NHL). [1] [2] [3] [4] [5] [6] [7] At the cytogenetic level, heterogeneous chromosomal breakpoints have been described ranging from 10p11 to 10p15 and 11q14 to 11q23. Molecular studies have helped clarify this heterogeneity by identifying several different fusion genes that result from t(10;11). The t(10;11)(p12;q23) is a translocation observed predominantly in the M4 and M5 subtypes of AML that fuses the 11q23 myeloid/lymphoid leukemia, or MLL (also known as HRX, HTRX-1 and ALL-1), gene to AF10, which encodes a member of a newly recognized class of zinc finger/leucine zipper proteins. 8, 9 Because AF10 and MLL are in opposite orientations, complex rearrangements involving more than two chromosomes and/or unusual inversions are required to produce a fusion gene that encodes for functional MLL-AF10 chimeras. 10 In one case, an inv ins(10;11) (p12;23q12) created centromeric MLL-AF10 and telomeric AF10-HEAB fusion genes.
11 AF10 is also fused to CALM, a gene that encodes a novel member of the clathrin assembly protein family, by a t(10;11)(p13;q14) in the U937 cell line Correspondence: SP Hunger, UCHSC Campus Box C229, 4200 East Ninth Ave, Denver, CO 80262, USA; Fax: 303 315 3244 Received 12 January 1998; accepted 5 May 1998 which was originally derived from a diffuse histiocytic lymphoma. 12 Additional leukemias and lymphomas containing t(10;11)(p13;q14-21) have been described, most of which are T lineage ALLs (T-ALL). 5, 6, 10, 12 Recently, Kobayashi et al 13 demonstrated by fluorescence in situ hybridization (FISH) that AF10 and CALM were involved in four patients with diverse hematological malignancies (one AML with monocytic features, one ALL, one lymphoblastic lymphoma and one granulocytic sarcoma) containing a t(10;11)(p13;q21). However, the molecular details of AF10 and CALM abnormalities in leukemias or lymphomas containing a t(10;11)(p13-14;q14-21) have not been reported in cases other than U937.
In this report, we describe analyses of a case of T-ALL that contained a t(10;11)(p13-14;q14-21). Multiple different isoforms of AF10-CALM and CALM-AF10 fusion cDNAs, which arose via alternative splicing of both AF10 and CALM, were amplified from this leukemia. We found that wild-type AF10 and CALM can also undergo alternative splicing, and identified at least two novel AF10 exons. The majority of the AF10 and AF10-CALM isoforms we identified are predicted to encode for truncated AF10 polypeptides, raising the possibility that these might have important cellular functions, perhaps by acting as dominant negative inhibitors of full-length AF10 or related proteins.
Materials and methods

Cytogenetics
Mitotic figures were obtained from direct preparations of bone marrow aspirates using minor modifications of a previously described technique.
14 Cytogenetic analysis was performed using G-banded chromosomes. 15 The karyotype was described using the International System for Cytogenetic Nomenclature (ISCN 1995). 16 
Molecular Studies
Cryopreserved leukemic specimens were analyzed under a protocol approved by the Institutional Review Board of the University of Colorado Health Sciences Center. To search for MLL gene rearrangements, a Southern blot containing BamHIdigested genomic DNA was hybridized with the B9 MLL cDNA probe as previously described. 17 To perform reverse transcriptase-polymerase chain reaction (RT-PCR) analyses, total RNA was extracted from cryopreserved bone marrow aspirates by RNAzol B (TEL-TEST, Friendswood, TX, USA). One g of total RNA was converted to cDNA with Superscript RT (Gibco BRL, Gaithersburg, MD, USA) and random hexamer primers. The oligomers (see Table 1 for sequences) AN.B497 + AN.T288 were used to amplify AF10-CALM cDNAs, CA1870 + AF532 to amplify CALM-AF10 cDNAs, CA1870 + AN.B497 to amplify CALM cDNAs, and AN.T288 + AF532 to amplify AF10 cDNAs. To confirm that A and B were bona fide AF10 exons, cloned RT-PCR products and genomic DNA isolated from normal individuals were amplified with the following oligomers: AF394 + NA.B628, AF394 + exon A 3′, exon A 5′ + NA.B628, AF394 + exon B 3′, and exon B 5′ + NA.B628. To confirm the integrity of isolated RNA, a portion of the Abl cDNA was amplified using previously described primers. 18 RNA extracted from cell lines, K562 (CML) and JD2 (ALL), containing (9;22) translocations was also subjected to amplification. As negative controls, reactions lacking input cDNA were also subjected to amplification.
The PCR reaction mix contained 50 pmol of each primer, 200 mM dNTPs, 50 mM KCl, 10 mM Tris-HCl pH 8.3, 1.5 mM MgCl 2 , 0.001% gelatin, and 2.5 units of AmpliTaq Gold polymerase (Perkin Elmer, Foster City, CA, USA) in a voluem of 50 l. Amplifications were performed in a GeneAmp PCR 9600 for 35 cycles, annealing temperatures were optimized for each set of primers based upon the estimated T m of the oligomers. Twenty microliter aliquots of the PCR products were electrophoresed in 3% agarose 3:1 high resolution blend (Amresco, Solon, OH, USA) gels stained with ethidium bromide. Gels were photographed with UVP Gel Documentation System GDS7500 (UVP, Upland, CA, USA).
To determine the nucleotide sequence of PCR products, 1 l of the product was ligated into the pCRII vector (Invitrogen, Carlsbad, CA, USA) and used to transform competent bacteria exactly as suggested by the manufacturer. Twenty independent colonies were isolated for each ligation and the size of the cloned PCR product was determined following digestion with restriction endonucleases that recognized flanking sites in the vector backbone. The nucleotide sequences of PCR products were determined on both strands using the Sequenase 2.1 kit (USB). Data base searches were performed using the BLAST algorithm through the web site of the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/BLAST/).
Case History
A 17-year-old white female was diagnosed with ALL with central nervous system (CNS) involvement after a white blood cell count of 102 000/l with 97% leukemic blasts was found on a routine complete blood count obtained prior to elective knee /day × 4 days), and cranial radiation (2400 cGy). Two weeks later, she experienced a bone marrow relapse without evidence of CNS disease. She then received Ara-C (3 g/m 2 every 12 h × 4) and VP-16 (200 mg/m 2 /day × 2), but had persistent leukemic blasts in the peripheral blood. Following this, she was treated with intravenous methotrexate (1.5 g/m 2 over the first hour followed by 300 mg/m 2 /h over the next 23 h) and vincristine (1.5 mg/m 2 ) weekly for 2 weeks and attained a second complete remission. She then underwent an allogeneic bone marrow transplant (BMT) from a 4 of 6 antigen-matched related donor, but died post-BMT of severe graft-versus-host disease. No histologic evidence of leukemia was detected at autopsy.
Results
Cytogenetic studies from a bone marrow aspirate obtained at diagnosis revealed a karyotype of 47,XX,t(10;11) (p15;q23),+20 [7] /46,XX [7] . This acquired clone was not identified in subsequent bone marrow aspirates, none of which were available for molecular analysis. Several years later, DNA obtained from leukemic cells cryopreserved at the time of initial diagnosis was analyzed for MLL rearrangements by Southern blot analysis. No rearranged bands were identified ( Figure 1 ). In addition, interphase FISH analysis with an MLL probe showed no evidence of MLL abnormalities (data not shown). Because of these findings, and the report of AF10-CALM fusion in U937, 12 the original karyotype was re-examined. In this review, the translocation was described with more proximal breakpoints: t(10;11)(p13-14;q14-21).
Figure 1
The t(10;11) + T-ALL does not contain MLL rearrangements. Autoradiogram of a blot containing BamH1-digested genomic DNA that was hybridized with an MLL cDNA probe. Samples include a normal control, the t(4;11)-positive MV4;11 cell line, a patient with t(6;11)-positive AML, the T-ALL patient with a t(10;11), and AML and ALL patients lacking 11q23 cytogenetic abnormalities. The location of the germline MLL band is indicated on the right and the migration of molecular size markers on the left.
To determine whether AF10-CALM fusion was present in this T-ALL, we performed RT-PCR using 5′ AF10 and 3′ CALM oligomers (Figure 2a) . At least five different-sized PCR products were amplified from the t(10;11) patient, but not from control cell lines lacking a t(10;11). These PCR products were then cloned into a plasmid vector. Twenty clones were identified, found to segregate into five classes of unique size, and the nucleotide sequence of representative individual clones was determined. These clones represented five distinct isoforms of AF10-CALM fusion cDNAs (Figure 2b) . Sequencing of multiple wild-type and fusion cDNAs (see below) allowed us to define the exon borders more precisely than was possible in earlier reports. The junction between AF10 and CALM sequences in the isoform that we refer to as type I is identical to that in the AF10-CALM fusion cDNA previously isolated from U937. 12 The other four isoforms resulted from alternative usage of different exons of both AF10 and CALM (thoughout this report, numbering of AF10 conforms to that reported by Chaplin et al, 8 and CALM to that reported by Dreyling et al 12 ). The type III isoform contained 52 nucleotides at the AF10-CALM junction which were not homologous to sequences in the GenBank data base. As demonstrated below, these are derived from an alternatively-spliced AF10 exon. Each of these isoforms is predicted to encode for small peptides containing the first 53 or 80 AF10 residues. Stop codons are present within 5-7 codons of this portion of AF10 in type I, II and III isoforms. Isoforms IV and V contain the carboxyterminal 60 and 40 CALM residues, respectively.
To determine the origin of the novel sequences present in type III AF10-CALM cDNAs and further characterize the splicing that occurs in wild-type and fusion transcripts, we amplified the reciprocal CALM-AF10 fusion cDNA from the t (10;11) + patient, and amplified wild-type CALM and AF10 cDNAs from the cell lines K562 and JD2. CALM-AF10 PCR products were obtained only from the t (10;11) + patient, whereas wild-type cDNAs were amplified from the patient and the two cell lines (data not shown). This is consistent with prior observations that AF10 and CALM are both transcribed in hematopoietic cells. 12 The various PCR products were cloned, analyzed and sequenced as described above. Alternative splicing was observed for each gene (Figure 3) .
We observed two types (II and III in Figure 3b ) of CALM-AF10 fusion cDNAs, both of which are different than type I cDNAs described previously (Figure 3a) . The genomic breakpoint in the T-ALL we analyzed is located more 5′ in CALM than the U937 breakpoint, as we could not amplify CALM-AF10 cDNAs (but could amplify wild-type CALM cDNAs) with an oligomer homologous to CALM nucleotides 1934-1954 (data not shown). Type I and II CALM-AF10 cDNAs are predicted to encode polypeptides that include most of CALM (648 or 593 of the predicted 652 residues) fused to residues 81-1027 of AF10. Type III CALM-AF10 cDNAs are predicted to encode a polypeptide that contains almost all of CALM, followed by 56 amino acids specified by an alternative AF10 reading frame.
Most (8/9) of the bona fide wild-type CALM cDNAs we amplified were identical to those previously described (type I in Figure 3b ). One PCR product was missing CALM nucleotides 1927-1986. This is likely due to alternative splicing of a single exon, as we can infer that nucleotide 1926 is the 3′ border of an exon and 1987 is the 5′ border of an exon from the junctions observed in various fusion cDNAs (see Figure 4) . These type II CALM cDNAs are predicted to encode a protein lacking amino acids 594-613. Eight of the 17 CALM PCR products we cloned contained the 5′ and 3′ amplification primers separated by 83 nucleotides of unknown origin (data not shown). These products most likely resulted from spurious priming, as the interspersed sequence shared homology with microsatellite repeats from various organisms. Furthermore, we did not identify products containing these sequences when amplifications were performed with more 5′ or 3′ primers (data not shown).
Five distinct types of wild-type AF10 cDNAs were amplified from K562 (Figure 3b ). Type I cDNAs were identical to those previously described. Type II and III cDNAs arose via alternative splicing that removed single, or, less likely, two small, exons. These cDNAs are predicted to code for truncated polypeptides that include the amino terminal 53 (type II) or 80 (type III) amino acids of AF10. Type IV AF10 cDNAs include the identical 52 nucleotides present in Type III AF10-CALM fusion cDNAs, indicating that these are derived from an alternatively spliced AF10 exon that has not previously been described (exon A in Figure 4a ). Type V cDNAs were found to contain 99 nucleotides of unknown origin between nucleotides 423 and 424. As AF10 cDNAs frequently exhibit alternative splicing, we hypothesized that these derived from another previously unidentified AF10 exon. To confirm that the sequences referred to as exons A and B in Figure 4 are derived from alternative exons, we performed PCR with several differ- ent primer/pairs (see Methods) on genomic DNA isolated from two healthy individuals and cloned RT-PCR products (data not shown). Results of these studies demonstrated that AF10 nucleotides 423 and 424 (Figure 4a ) are separated by about 360 bp of genomic DNA. A and B are indeed bona fide alternative exons, and not adjacent intron sequence derived from contaminating genomic DNA, because larger PCR products were amplified from genomic DNA than from the cloned RT-PCR products when amplifications were performed in both directions. Both the A and B alternative exons included in type IV and V AF10 cDNAs include in-frame stop codons; thus, these cDNAs are predicted to encode for truncated AF10 polypeptides consisting of the amino terminal 80 residues followed by 6 (type IV) or 13 (type V) additional novel residues (Figure 4a ).
Discussion
Our studies extend previous FISH studies 13 and provide direct molecular evidence that AF10-CALM fusion occurs in primary leukemias as well as in the U937 cell line, which was derived from a tumor originally described as a diffuse histiocytic lymphoma but displays many myeloid features.
1,2 The AF10-CALM and CALM-AF10 fusion cDNAs isolated from U937 and the case described in this report are quite similar, suggesting that differences in the sites of mRNA fusion are unlikely to explain the phenotype heterogeneity observed in leukemias and lymphomas with this molecular abnormality. Further studies of additonal leukemias containing a t(10;11) are necessary to define the percentage of cases that contain MLL-AF10 vs AF10-CALM fusion, and the clinical features associated with each molecular subtype of leukemia.
As was true for U937, 12 the T-ALL we examined expressed both AF10CALM and CALM-AF10 fusion transcripts. At this point in time, there are no data to indicate which of the chimeric proteins theoretically encoded by these transcripts is important for leukemogenesis. A definitive answer to this question must await establishment of appropriate functional assays in which the transforming properties of AF10-CALM and CALM-AF10 can be tested. Dreyling et al 12 have argued, based on the fact that it contains most of the functional domains present in each wild-type protein, that CALM-AF10 is likely to be the critical leukemogenic protein. While this is certainly a reasonable hypothesis, it is striking that each of the five types of AF10-CALM cDNAs we observed are predicted to encode for proteins that include the amino terminal 53 or 80 AF10 residues followed by 6-60 additional residues encoded by in-or out-of-frame CALM sequences. Furthermore, four of the five types of wild-type AF10 cDNAs we observed are predicted to encode for short AF10 polypeptides that contain little more than the same amino terminal 53 or 80 resi- dues. In two cases this involves differential splicing of exons that contain in-frame stop codons, which would seem to make it less likely that we are simply detecting amplification of aberrantly spliced RNAs.
Our findings raise the possibility that truncated AF10 polypeptides might have important cellular functions. The AF10 amino terminus contains a cysteine-rich motif, the LAP (leukemia-associated protein) domain, that has been postulated to be a zinc finger-like DNA binding domain. 19 The core LAP domain (homologous to AF10 residues 22-74) is present in approximately two dozen proteins, including MLL and its rodent and fly homologues, Drosophila Pcl (polycomb-like) protein and Requiem, a murine protein necessary for apoptosis in myeloid cells.
19 AF10; AF17, another MLL translocation partner; BR140, a human protein of unknown function; and CEZF, a protein encoded by a putative Caenorhabditis elegans gene, contain larger regions of shared homology that extend approximately 100 amino acids carboxy-terminal to the core LAP domain. 19 Perhaps truncated AF10 polypeptides function as dominant negative inhibitors of full-length AF10 or related proteins. Based on these factors, the potential role of truncated AF10 proteins in normal cells and in leukemias with a t(10;11)(p13;q14) must be considered. In the future, it will be important to develop antibodies that recognize the amino terminus of AF10 to determine whether or not truncated polypeptides are present in normal and leukemic cells.
Note added in proof
The cDNA sequences described in this report have been deposited in GenBank (accession numbers AF060927-AF060940).
